Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Is intensive antiplatelet therapy more effective in preventing recurrent stroke or transient ischemic attacks than standard antiplatelet therapy in patients with acute cerebral ischemia?
Bottom line
Intensive antiplatelet therapy given after acute noncardioembolic cerebral ischemia is no better at preventing recurrent events than standard therapy, but doubles the chances of major or fatal bleeding. 1b-
Reference
Study design: Randomized controlled trial (single-blinded)
Funding: Government
Setting: Inpatient (any location) with outpatient follow-up
Synopsis
Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (TARDIS) is a multinational multicenter study in which 3100 adults with a noncardioembolic transient ischemic attack (TIA) or acute ischemic stroke were randomized within 48 hours of symptoms to receive intensive antiplatelet therapy ("triple therapy"—consisting of aspirin, clopidogrel, and dipyridamole) or standard guideline-directed therapy with aspirin or clopidogrel plus dipyridamole. Although this was an open-label trial, research staff unaware of treatment allocation performed the outcome assessments 90 days after enrollment. In addition to assessing recurrent stroke or TIA, the researchers evaluated the severity of the events and various measures of function and quality of life. Finally, they also assessed bleeding complications: fatal, major, moderate, minor, and none. The study design called for enrolling 4100 patients; however, the safety and monitoring committee stopped the study early. At the time the trial was stopped, there was no difference in the rate of recurrent events, but 20% of the patients who received triple therapy experienced bleeding compared with 9% of the standard-therapy patients (number needed to treat to harm [NNTH] = 10; 95% CI 8 - 13). Furthermore, the patients who received triple therapy were twice as likely to have major or fatal bleeding (2.5% vs 1.1%; NNTH = 71; 42 - 210).
Reviewer
Henry C. Barry, MD, MS
Professor
Michigan State University
East Lansing, MI
Comments
Reference is to "guideline-based therapy (comprising either clopidogrel alone or combined aspirin and dipyridamole)". What guidelines do the authors refer to?
good poem
Good to see updated info on antiplatelet use in TIA.
It is reassuring that more anti platelets use is not better. It is not only safer for the patients but also saves money directly as in the cost of the drugs and indirectly in hospitalization following increased bleed.